Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) went up by 15.28% from its latest closing price compared to the recent 1-year high of $42.81. The company’s stock price has collected 17.59% of gains in the last five trading sessions.
Is It Worth Investing in Recursion Pharmaceuticals Inc. (NASDAQ :RXRX) Right Now?
Opinions of the stock are interesting as 1 analysts out of 5 who provided ratings for Recursion Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $15.60, which is $7.88 above the current price. RXRX currently public float of 133.18M and currently shorts hold a 10.53% ratio of that float. Today, the average trading volume of RXRX was 1.08M shares.
RXRX’s Market Performance
RXRX stocks went up by 17.59% for the week, with a monthly jump of 35.59% and a quarterly performance of 6.28%, while its annual performance rate touched -79.08%. The volatility ratio for the week stands at 12.80% while the volatility levels for the past 30 days are set at 10.05% for Recursion Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 19.78% for RXRX stocks with a simple moving average of -44.34% for the last 200 days.
Analysts’ Opinion of RXRX
Many brokerage firms have already submitted their reports for RXRX stocks, with BofA Securities repeating the rating for RXRX by listing it as a “Neutral.” The predicted price for RXRX in the upcoming period, according to BofA Securities is $10 based on the research report published on April 18th of the current year 2022.
SVB Leerink, on the other hand, stated in their research note that they expect to see RXRX reach a price target of $10. The rating they have provided for RXRX stocks is “Mkt Perform” according to the report published on March 04th, 2022.
Berenberg gave a rating of “Buy” to RXRX, setting the target price at $37 in the report published on September 21st of the previous year.
RXRX Trading at 20.22% from the 50-Day Moving Average
After a stumble in the market that brought RXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.20% of loss for the given period.
Volatility was left at 10.05%, however, over the last 30 days, the volatility rate increased by 12.80%, as shares surge +38.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.59% upper at present.
During the last 5 trading sessions, RXRX rose by +17.59%, which changed the moving average for the period of 200-days by -69.25% in comparison to the 20-day moving average, which settled at $6.47. In addition, Recursion Pharmaceuticals Inc. saw -55.52% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RXRX starting from Gibson Christopher, who sale 2,500 shares at the price of $6.34 back on Jun 02. After this action, Gibson Christopher now owns 0 shares of Recursion Pharmaceuticals Inc., valued at $15,859 using the latest closing price.
Gibson Christopher, the Chief Executive Officer of Recursion Pharmaceuticals Inc., sale 39,690 shares at $6.09 during a trade that took place back on Jun 02, which means that Gibson Christopher is holding 516,268 shares at $241,766 based on the most recent closing price.
Stock Fundamentals for RXRX
Current profitability levels for the company are sitting at:
- -1795.79 for the present operating margin
- +10.55 for the gross margin
The net margin for Recursion Pharmaceuticals Inc. stands at -1832.18. Equity return is now at value -37.20, with -31.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 11.46.